MK-7339
Total Payments
$21.9M
Transactions
5,779
Doctors
76
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2020 | $19.0M | 4,499 | 47 |
| 2019 | $2.9M | 1,278 | 49 |
| 2018 | $691.64 | 2 | 1 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $20.5M | 5,056 | 93.4% |
| Consulting Fee | $1.4M | 516 | 6.4% |
| Travel and Lodging | $22,480 | 85 | 0.1% |
| Food and Beverage | $5,778 | 121 | 0.0% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $17.99 | 1 | 0.0% |
Payments by Type
Research
$20.5M
5,056 transactions
General
$1.4M
723 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olaparib or Placebo for the First-Line Treatment of BRCA non-mutated Advanced Epithelial Ovarian Cancer EOC | Merck Sharp & Dohme Corporation | $4.7M | 0 |
| A Phase 3 Study of Pembrolizumab in Combination with Pemetrexed,Platinum Carboplatin or Cisplatin Followed by Pembrolizumab and Maintenance Olaparib vs Maintenance Pemetrexed in the First-Line Treatment of Participants with Metastatic Nonsquamous Non-Small-Cell Lung Cancer | Merck Sharp & Dohme Corporation | $2.7M | 0 |
| A Phase 3, Randomized, Open-label Study of Pembrolizumab MK-3475 Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castration-resistant Prostate Cancer mCRPC Who are Unselected for Homologous Recombination Repair Defects and Have Failed Prior Treatment with One Next-generation Hormonal Agent NHA and Chemotherapy MK7339-010 | Merck Sharp & Dohme Corporation | $2.6M | 0 |
| A Phase 2 Study of Olaparib in Combination with Pembrolizumab in Participants with Previously Treated, Homologous Recombination Repair Mutation HRRm and,or Homologous Recombination Deficiency HRD Positive Advanced Cancer | Merck Sharp & Dohme Corporation | $2.6M | 0 |
| A Phase 3 Study of Pembrolizumab in Combination with Carboplatin,Taxane Paclitaxel or Nab-paclitaxel Followed by Pembrolizumab with or without Maintenance Olaparib in the First-line Treatment of Metastatic Squamous Non-small Cell Lung Cancer NSCLC | Merck Sharp & Dohme Corporation | $2.4M | 0 |
| An Open-label, Randomized, Phase 2,3 Study of Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After Induction of Clinical Benefit With First-line Chemotherapy Plus Pembrolizumab in Participants With Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer TNBC KEYLYNK 009 | Merck Sharp & Dohme Corporation | $1.2M | 0 |
| A Phase 3 Study of Pembrolizumab MK-3475 in Combination with Concurrent Chemoradiation Therapy Followed by Pembrolizumab with or without Olaparib vs Concurrent Chemoradiation Therapy Followed by Durvalumab in Participants with Unresectable, Locally Advanced, Stage III Non-Small Cell Lung Cancer NSCLC | Merck Sharp & Dohme Corporation | $1.2M | 0 |
| A Phase 2 Study of Olaparib Monotherapy in Participants with Previously Treated, Homologous Recombination Repair Mutation HRRm or Homologous Recombination Deficiency HRD Positive Advanced Cancer | Merck Sharp & Dohme Corporation | $797,088 | 0 |
| A Phase 3 Study of Pembrolizumab in Combination with Carboplatin,TaxanePaclitaxel or Nab-paclitaxel Followed by Pembrolizumab with or without MaintenanceOlaparib in the First-line Treatment of Metastatic Squamous Non-small Cell Lung CancerNSCLC | Merck Sharp & Dohme Corporation | $654,028 | 0 |
| A Phase 2 Trial to Evaluate the Safety and Antitumor Activity of Pembrolizumab and OLApaRib POLAR for Individuals with Metastatic Pancreatic Ductal Adenocarcinoma and Homologous Recombination Deficiency | Merck Sharp & Dohme Corporation | $633,732 | 0 |
| Immunotherapy in combination with PARP inhibition in advanced cervical cancer patients functionally competent or deficient for the Fanconi Anemia repair pathway | Merck Sharp & Dohme Corporation | $341,256 | 0 |
| A Phase 3 Randomized, Open-label Study to Evaluate the Efficacy and Safety of Olaparib Alone or in Combination With Bevacizumab Compared to Bevacizumab With 5-FU in Participants with Unresectable or Metastatic Colorectal Cancer who Have not Progressed Following First-line Induction of FOLFOX With Bevacizumab LYNK-003. | Merck Sharp & Dohme Corporation | $260,337 | 0 |
| A Randomized, Double-blind, Placebo-controlled Phase 3 Study of Pembrolizumab MK-3475 in Combination with Concurrent Chemoradiation Therapy Followed by Pembrolizumab with or without Olaparib MK-7339, Compared to Concurrent Chemoradiation Therapy Alone in Participants with Newly Diagnosed Treatment-Na ve Limited-Stage Small Cell Lung Cancer LS-SCLC | Merck Sharp & Dohme Corporation | $208,768 | 0 |
| Understanding Treatment Patterns, Resource Use, and Patient Outcomes Associated with Novel Treatments in Ovarian Cancer | Merck Sharp & Dohme Corporation | $138,104 | 0 |
| A Phase 3 Study of Pembrolizumab in Combination with Etoposide,Platinum Cisplatin or Carboplatin Followed by Pembrolizumab with or without Maintenance Olaparib in the First-line Treatment of Participants with Extensive Stage Small Cell Lung Cancer ES SCLC | Merck Sharp & Dohme Corporation | $105,064 | 0 |
| Phase II study of olaparib in combination with pembrolizumab in patients with advanced melanoma with homologous recombination HR pathway gene mutation | Merck Sharp & Dohme Corporation | $36,576 | 0 |
Ad
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $21.9M
- Total Doctors 76
- Transactions 5,779
About MK-7339
MK-7339 is a drug associated with $21.9M in payments to 76 healthcare providers, recorded across 5,779 transactions in the CMS Open Payments database. The primary manufacturer is Merck Sharp & Dohme Corporation.
Payment data is available from 2018 to 2020. In 2020, $19.0M was paid across 4,499 transactions to 47 doctors.
The most common payment nature for MK-7339 is "Unspecified" ($20.5M, 93.4% of total).
MK-7339 is associated with 16 research studies, including "A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olaparib or Placebo for the First-Line Treatment of BRCA non-mutated Advanced Epithelial Ovarian Cancer EOC" ($4.7M).